Citations

Citations to this article as recorded by  

• Precision Oncology in Lung Cancer Surgery
  Patrick Bou-Samra, Sunil Singhal
  Surgical Oncology Clinics of North America.2024; 33(2): 311.     CrossRef
• Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience
  Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya
  Egyptian Liver Journal.2024;[Epub]     CrossRef
• Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responses
  Hong Zhang, Yinlin Luo, Xincheng Zhao, Xiande Liu
  Molecular Therapy: Oncology.2024; 32(1): 200770.     CrossRef
• Unlocking the potential of oncology biomarkers: advancements in clinical theranostics
  Ankit Kumar Dubey, Ishnoor Kaur, Reecha Madaan, Shikha Raheja, Rajni Bala, Manoj Garg, Suresh Kumar, Viney Lather, Vineet Mittal, Deepti Pandita, Rohit Gundamaraju, Rajeev K. Singla, Rohit Sharma
  Drug Metabolism and Personalized Therapy.2024; 39(1): 5.     CrossRef
• Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
  Uiju Cho, Soyoung Im, Hyung Soon Park
  Journal of Pathology and Translational Medicine.2024; 58(2): 49.     CrossRef
• Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling
  Miriam Schirru, Hamza Charef, Khalil-Elmehdi Ismaili, Frédérique Fenneteau, Didier Zugaj, Pierre-Olivier Tremblay, Fahima Nekka
  Journal of Pharmacokinetics and Pharmacodynamics.2024;[Epub]     CrossRef
• Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma
  Seong Hee Yeo, Hyun Jung Yoon, Injoong Kim, Yeo Jin Kim, Young Lee, Yoon Ki Cha, So Hyeon Bak
  Journal of the Korean Society of Radiology.2024; 85(2): 394.     CrossRef
• Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
  Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei, Wenchuan Xie, Cheng Zhang, Hougang Zhang, Chan Gao, Xiaochen Zhao, Yuezong Bai, Caicun Zhou, Shengxiang Ren
  International Journal of Cancer.2023; 152(1): 79.     CrossRef
• Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma
  Jiwon Koh, Haeryoung Kim, Kyung Chul Moon, Cheol Lee, Kyoungbun Lee, Han Suk Ryu, Kyeong Cheon Jung, Yoon Kyung Jeon
  American Journal of Surgical Pathology.2023; 47(2): 183.     CrossRef
• Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
  Moonsik Kim, Ji Yun Jeong, An Na Seo
  Diagnostics.2023; 13(17): 2782.     CrossRef
• PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
  Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer
  Cancers.2023; 15(18): 4471.     CrossRef
• Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis
  Jeongwan Kang, Kang Min Han, Hera Jung, Hyunchul Kim
  Diagnostics.2023; 13(20): 3258.     CrossRef
• A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
  Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, Lasse Westphal Thomsen, Torben Steiniche, Magnus Stougaard
  Experimental and Molecular Pathology.2022; 125: 104749.     CrossRef
• Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
  Swati Satturwar, Ilaria Girolami, Enrico Munari, Francesco Ciompi, Albino Eccher, Liron Pantanowitz
  Diagnostic Cytopathology.2022; 50(6): 313.     CrossRef
• Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
  Yen-Yu Lin, Lei-Chi Wang, Yu-Han Hsieh, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Yen-Yin Lin, Teh-Ying Chou
  Journal of Translational Medicine.2022;[Epub]     CrossRef
• Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
  Cristina-Florina Pirlog, Horia Teodor Cotan, Andreea Parosanu, Cristina Orlov Slavu, Ana Maria Popa, Cristian Iaciu, Mihaela Olaru, Alexandru Vlad Oprita, Irina Nita, Cornelia Nitipir
  Cureus.2022;[Epub]     CrossRef
• Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
  Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch
  Virchows Archiv.2022; 481(3): 351.     CrossRef
• Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
  Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai
  Biomedicines.2022; 10(7): 1539.     CrossRef
• Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites
  Wenqi Ti, Tianhui Wei, Jianbo Wang, Yufeng Cheng
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer
  Kai Hong, Yingjue Zhang, Lingli Yao, Jiabo Zhang, Xianneng Sheng, Lihua Song, Yu Guo, Yangyang Guo
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• Molecular imaging of immune checkpoints in oncology: Current and future applications
  Shushan Ge, Tongtong Jia, Jihui Li, Bin Zhang, Shengming Deng, Shibiao Sang
  Cancer Letters.2022; 548: 215896.     CrossRef
• PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
  Katerina Hadrava Vanova, Ondrej Uher, Leah Meuter, Suman Ghosal, Sara Talvacchio, Mayank Patel, Jiri Neuzil, Karel Pacak
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
  Nicoletta Provinciali, Marco Greppi, Silvia Pesce, Mariangela Rutigliani, Irene Maria Briata, Tania Buttiron Webber, Marianna Fava, Andrea DeCensi, Emanuela Marcenaro
  Frontiers in Immunology.2022;[Epub]     CrossRef
• PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
  John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill
  Endocrine Pathology.2021; 32(3): 408.     CrossRef
• Comprehensive tumor molecular profile analysis in clinical practice
  Mustafa Özdoğan, Eirini Papadopoulou, Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou, Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassa
  BMC Medical Genomics.2021;[Epub]     CrossRef
• CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study
  Zekun Jiang, Yinjun Dong, Linke Yang, Yunhong Lv, Shuai Dong, Shuanghu Yuan, Dengwang Li, Liheng Liu
  Journal of Digital Imaging.2021; 34(5): 1073.     CrossRef
• Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
  Pierre Murchan, Cathal Ó’Brien, Shane O’Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib Ó Broin, Stephen P. Finn
  Diagnostics.2021; 11(8): 1406.     CrossRef
• Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic
  David Leung, Samuel Bonacorsi, Ralph Adam Smith, Wolfgang Weber, Wendy Hayes
  Frontiers in Oncology.2021;[Epub]     CrossRef
• A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma
  Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Ma
  Lung Cancer Management.2021;[Epub]     CrossRef
• Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
  Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi
  Thoracic Cancer.2021; 12(5): 603.     CrossRef
• Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis
  Qiong-ying Hu, Yun Yuan, Yu-chen Li, Lu-yao Yang, Xiang-yu Zhou, Da-qian Xiong, Zi-yi Zhao, Hiroshi Tanaka
  BioMed Research International.2021; 2021: 1.     CrossRef
• PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
  Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánch
  Lung Cancer Management.2021;[Epub]     CrossRef
• Can Systems Biology Advance Clinical Precision Oncology?
  Andrea Rocca, Boris N. Kholodenko
  Cancers.2021; 13(24): 6312.     CrossRef
• Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
  Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
  Cancer Cytopathology.2020; 128(3): 160.     CrossRef
• Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
  Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna
  Journal of Translational Medicine.2020;[Epub]     CrossRef
• Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India
  Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra
  Current Problems in Cancer.2020; 44(3): 100549.     CrossRef
• Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
  Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi
  Thoracic Cancer.2020; 11(4): 993.     CrossRef
• Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm
  Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström
  Scandinavian Journal of Clinical and Laboratory Investigation.2020; 80(5): 360.     CrossRef
• Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
  Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli
  European Journal of Cancer.2020; 131: 40.     CrossRef
• Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
  Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
  Cancers.2020; 12(5): 1125.     CrossRef
• Current status and future perspectives of liquid biopsy in non-small cell lung cancer
  Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
  Journal of Pathology and Translational Medicine.2020; 54(3): 204.     CrossRef
• Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
  Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena V. Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis, Giancarlo
  Cancers.2020; 12(7): 1800.     CrossRef
• PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
  Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors, Grazyna Kochan
  International Journal of Molecular Sciences.2020; 21(16): 5918.     CrossRef
• PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
  Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth St
  Gynecologic Oncology.2020; 159(2): 322.     CrossRef
• Atezolizumab: A Review in Extensive-Stage SCLC
  James E. Frampton
  Drugs.2020; 80(15): 1587.     CrossRef
• Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis
  Hyun Min Koh, Bo Gun Jang, Hyun Ju Lee, Chang Lim Hyun
  Thoracic Cancer.2020; 11(11): 3086.     CrossRef
• Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten
  Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
  Kompass Pneumologie.2020; 8(6): 300.     CrossRef
• Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
  Lee, Kim, Sung, Lee, Han, Kim, Choi
  International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef
• Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
  João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
  Cancers.2019; 11(10): 1535.     CrossRef
• Basis of PD1/PD-L1 Therapies
  Barbara Seliger
  Journal of Clinical Medicine.2019; 8(12): 2168.     CrossRef